The Panels Complete Bio-Rad’s Set of Bio-Plex™ Pro Multiplex SARS-CoV-2 Human Serology Panels for Detection of Antibodies Against Four SARS-CoV-2 Antigens
HERCULES, Calif. —Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Bio-Plex™ Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The panels are for research use only (RUO).
The Bio-Plex™ Pro Human IgA SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel and the Bio-Plex™ Pro Human IgM SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel join Bio-Rad’s existing Bio-Plex™ Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel to complete the set of three separate qualitative multiplex immunoassays that provide precise and efficient detection of IgA, IgG, and IgM antibodies against four SARS-CoV-2 antigens. The panels assist researchers in developing vaccines, and the panels also help public health researchers who perform seroprevalence studies based on serology specimens to identify individuals who may have been exposed to SARS-CoV-2. These individuals may have not been diagnosed with COVID-19 and could have experienced only mild symptoms, or they could be asymptomatic.
“The multiplex immunoassay panels help vaccine developers determine therapeutic efficacy, from development through clinical phases and then later on in postmarket surveillance studies,” said Candice Cox, Bio-Rad Immunoassays Marketing Manager, Life Science Group. “Detecting levels of antibodies against SARS-CoV-2 in an individual provides valuable information about possible exposure rates in a population or about the effectiveness of COVID-19 vaccines in preventing the spread of this disease,” she said.
About the Bio-Plex Pro Human SARS-CoV-2 Serology Panels
The Bio-Plex™ Pro Human IgA, IgG, and IgM SARS-CoV-2 panels are three separate ready-to-use 96-well kits containing premixed magnetic capture beads, an isotype-specific detection antibody, positive and negative controls, and buffers, to produce results for four anti–SARS-CoV-2 antibodies. Individual components such as viral antigen–coupled beads are offered as singleplex assay reagents for multispecies assay development that enables measurement of antibodies against specific viral antigens of interest while improving research laboratory efficiency.
Key Benefits
- Can be provided as a kit that includes all required reagents
- Help researchers simultaneously profile antibodies against four SARS-CoV-2 viral antigens: the nucleocapsid protein (N) and the receptor binding domain (RBD), and the spike 1 (S1) and spike 2 subunits (S2) of the spike protein
- Provide results in less than 3 hours
- Enable comparison of median fluorescence intensity (MFI) values of samples to help researchers and vaccine developers understand the strength of response and antibody levels at different time points after SARS-CoV-2 infection or vaccination
Please visit bio-rad.com/Bio-PlexCOVIDAbs for more information.
BIO-RAD and BIO-PLEX are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. The Bio-Plex Suspension Array System includes fluorescently labeled microspheres and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation. All trademarks used herein are the property of their respective owner.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,700 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contact:
Bio-Rad Laboratories, Inc
Nico Tuason, Sr. Marketing Manager
510-741-1000
nico_tuason@bio-rad.com
Zyme Communications
Dr. Michelle Ricketts
+44 (0)778 9053 885
michelle.ricketts@zymecommunications.com